Obesity
Conditions
Interventions
Sponsors
The Second Nanning People’s Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Based on WHO criteria (BMI ?>=30 kg/m^2) or combined with waist circumference/body fat percentage (e.g., BMI >=27.5 kg/m^2 for Asian populations). 2.Aged 18–65 years; 3.Confirm obesity duration (e.g., >=6 months) to exclude transient weight fluctuations. 4.Behavioral and Pharmacological Controls: Diet/Exercise: Participants must maintain stable lifestyle (e.g., no significant dietary/exercise changes in prior 3 months). Medications: Eligible if no use of metabolism-affecting drugs (e.g., hypoglycemics, anti-obesity agents); detailed documentation required.
Exclusion criteria
Exclusion criteria: 1.Gut microbiota modifiers: Medications: Antibiotics, PPIs, immunosuppressants, or systemic hormones within 3 months; probiotics/prebiotics within 1 month. GI disorders: IBD, IBS, or prior GI surgery (e.g., gastric bypass). Systemic diseases: Autoimmune disorders, malignancies, chronic hepatic/renal insufficiency. 2.Metabolic/endocrine confounders: Thyroid dysfunction (e.g., abnormal TSH levels), Cushing’s syndrome, or other endocrine disorders. 3.Behavioral/Physiological Exclusions: Recent weight fluctuation: >=5% change within 3 months (indicating non-stable obesity). Special diets: Ketogenic, very-low-carbohydrate, or high-dose supplement use. Substance use: Heavy alcohol (>40g/day [male]/>20g/day [female]) or smoking (>10 cigarettes/day). 4.Inability to provide fecal samples (e.g., severe constipation/diarrhea) Recent bowel preparation (e.g., within 1 month post-colonoscopy);
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Gut microbiota composition analysis (a/ß-diversity at phylum/genus levels); | — |
Secondary
| Measure | Time frame |
|---|---|
| Short-chain fatty acids (SCFAs);Bile acid profiles;IL-6?TNF-a?CRP?IL-1ß?hs-CRP;Glycolipid metabolism indexes: glucose, insulin, glycosylated hemoglobin, total cholesterol, triglycerides, high/low-density lipoprotein cholesterol; | — |
Countries
China
Contacts
Public ContactFeng Chen
The Second Nanning People’s Hospital
Outcome results
None listed